For the Inventor, By the Inventor

Enter assignee name

Zwijnaarde, Belgium

Ablynx N.v.

USPTO Granted Patents = 163

CIPO Patents = 24

EPO Patents = 83

Trademarks = 1

Forward Citations = 796

Loading Chart...

Loading Chart...

191 inventors (with patents filed for the assignee):

Marie-Ange Buyse (27 out of 54 patents)

Carlo Boutton (22 out of 32 patents)

Peter Vanlandschoot (20 out of 21 patents)

4. Catelijne Stortelers (20 out of 22 patents)

5. Guy Hermans (19 out of 19 patents)

6. Erik Depla (18 out of 37 patents)

7. Stephanie Staelens (17 out of 22 patents)

8. Els Anna Alice Beirnaert (17 out of 17 patents)

9. Peter Schotte (16 out of 16 patents)

10. Michael John Scott Saunders (16 out of 24 patents)

11. Cedric Jozef Neotere Ververken (15 out of 15 patents)

12. Gerald Beste (15 out of 18 patents)

13. Soren Steffensen (14 out of 21 patents)

14. Joost Alexander Kolkman (13 out of 21 patents)

15. Sigrid Cornelis (12 out of 12 patents)

Core Competencies:

Antibody Purification

Immunoglobulin Single Variable Domains

Polypeptides Targeting IL-13

T Cell Recruiting Polypeptides

Tumor Growth Inhibition

Nanobody Dimers

Aerosol Preparation

Viral Disease Treatment

Chemokine Receptor Binding

Serum Albumin Binders

ADAMTS Binding Immunoglobulins

Glycosylated Immunoglobulins

163 patents: Sort by Forward Citations

1. 12479885 - Chromatography-free antibody purification method (2025-11-25),

2. 12384840 - Nucleic acids encoding polypeptides comprising immunoglobulin single variable domains targeting IL-13 and TSLP (2025-08-12),

3. 12384835 - Cysteine linked nanobody dimers (2025-08-12),

4. 12371496 - T cell recruiting polypeptides based on CD3 reactivity (2025-07-29),

5. 12285493 - Polypeptides antagonizing Wnt signaling in tumor cells (2025-04-29),

6. 12269893 - Methods of treating TTP with immunoglobulin single variable domains and uses thereof (2025-04-08),

7. 12221487 - Nucleic acids encoding CX3CR1-binding polypeptides comprising immunoglobulin single variable domains (2025-02-11),

8. 12209136 - ADAMTS binding immunoglobulins (2025-01-28),

9. 12180268 - Immunoglobulin variable domains (2024-12-31),

10. 12129308 - MMP13 binding immunoglobulins (2024-10-29),

11. 12116607 - Method for the production of domain antibodies (2024-10-15),

12. 12083219 - Methods and compositions for the preparation of aerosols (2024-09-10),

13. 12006352 - Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains (2024-06-11),

14. 11999797 - Methods of treating initial episode of TTP with immunoglobulin single variable domains (2024-06-04),

15. 11932702 - Polypeptides comprising immunoglobulin single variable domains targeting glypican-3 and T cell receptor (2024-03-19),

Ablynx N.V. is a biopharmaceutical company, specializing in the discovery, development, and commercialization of innovative Nanobodies. Their proprietary platform technology enables the creation of new, differentiated therapeutics to address a wide range of diseases, including inflammatory diseases, hematology, oncology, and respiratory diseases.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 23 2025

163 Patents

#1 in Zwijnaarde

#29 in Belgium

#4,921 in the World

Zwijnaarde, Belgium

Ablynx N.v.

Forward Citations = 796

191 inventors:

Marie-Ange Buyse (27 out of 54 patents)

Carlo Boutton (22 out of 32 patents)

Peter Vanlandschoot (20 out of 21 patents)

4. Catelijne Stortelers (20 out of 22 patents)

5. Guy Hermans (19 out of 19 patents)

Please report any incorrect information to support@idiyas.com

Loading…